Stocks · News reference
Combined company to focus on developing first-in-class next-generation medicines for cardioendocrine diseasesMarea has multiple late-stage clinical product candidates: MAR001/005 for severe hypertriglyceridemia (sHTG)
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-10-14 AccNo: 0001140361-26-039602 Size: 175 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
Trial follows promising MAR002 Phase 1 clinical trial results that demonstrated deep and durable IGF-1 suppression with PK properties that may enable dosing as infrequently as once every two weeks, compared to the daily
Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in private financing for Phase 2 clinical trials.